FDA reveals new drug tracing advice
This article was originally published in Scrip
Executive Summary
The FDA last week unveiled a new draft guidance, albeit a rather brief document, providing advice on how drug manufacturers, repackagers, wholesale distributors and dispensers should exchange transaction information, histories and statements when engaging in agreements involving certain prescription medicines to aid in tracing the products through the supply chain.